Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868626148Aexternal-prioritypatent/GB8626148D0/en
Priority claimed from GB878708531Aexternal-prioritypatent/GB8708531D0/en
Priority claimed from US07/036,807external-prioritypatent/US5041385A/en
Priority claimed from PCT/GB1987/000764external-prioritypatent/WO1988003563A1/en
Application filed by Oxford Gene SystemsfiledCriticalOxford Gene Systems
Publication of DK362088ApublicationCriticalpatent/DK362088A/da
Publication of DK362088D0publicationCriticalpatent/DK362088D0/da
Application grantedgrantedCritical
Publication of DK172990B1publicationCriticalpatent/DK172990B1/da
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
DK198803620A1986-11-011988-06-30Fusionsprotein, partikler omfattende dette, vaccine omfattende sådanne partikler, nukleinsyre, som koder for fusionsprotei
DK172990B1
(da)
Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut